
Drugs with Coverage Limitations and New Drug Review
Please Note:
- Date Review Completed and Conclusion columns are blank for those products currently undergoing review. Details will be updated as efficiently as possible following initial review.
- Conclusions are based upon decisions made at the time reviews are completed; historical information is not updated. Product management is subject to change based on new clinical evidence, provider/public feedback, advisory committee recommendations, financial considerations, etc.
- This contains approximately one year of New Drug details.
- Advisory Meeting Month is the month this recommendation will be presented at the quarterly Drug Prior Authorization Committee (DPAC) and Drug Utilization Review (DUR) Board meetings. For meeting dates, please see the MO HealthNet Calendar of Events. Certain agents may also be discussed at the quarterly Rare Disease Advisory Council meeting immediately prior to their presentation at their designated DPAC/DUR meeting.
For more information on this process please view the New Drug Review Process or contact the MO HealthNet Pharmacy Program at MHD.PharmacyAdmin@dss.mo.gov or call 573-751-6963.
Trade Name | Generic Name | Date Review Began | Date Review Completed | Conclusion | Advisory Committee Month |
---|---|---|---|---|---|
TAUVID VIAL | FLORTAUCIPIR F-18 | 07/24/2022 | 09/06/2022 | Open Access | December 2022 / January 2022 |
DYANAVEL XR 15 MG TABLET | AMPHETAMINE | 07/17/2022 | 08/30/2022 | PDL Edit | December 2022 / January 2022 |
DYANAVEL XR 5 MG TABLET | AMPHETAMINE | 07/17/2022 | 08/30/2022 | PDL Edit | December 2022 / January 2022 |
DYANAVEL XR 10 MG TABLET | AMPHETAMINE | 07/17/2022 | 09/06/2022 | Clinical Edit | December 2022 / January 2022 |
DYANAVEL XR 20 MG TABLET | AMPHETAMINE | 07/17/2022 | 08/30/2022 | PDL Edit | December 2022 / January 2022 |
QUVIVIQ 50 MG TABLET | DARIDOREXANT HCL | 07/03/2022 | 08/16/2022 | PDL Product | December 2022 / January 2022 |
ASPRUZYO SPRINKLE ER 1000 MG PKT | RANOLAZINE | 07/03/2022 | 08/30/2022 | PDL Edit | December 2022 / January 2022 |
QUVIVIQ 25 MG TABLET | DARIDOREXANT HCL | 07/03/2022 | 08/23/2022 | PDL Edit | December 2022 / January 2022 |
IBSRELA 50 MG TABLET | TENAPANOR HCL | 07/03/2022 | 08/16/2022 | Clinical Edit | December 2022 / January 2022 |
VTAMA 1% CREAM | TAPINAROF | 07/03/2022 | 08/16/2022 | PDL Product | December 2022 / January 2022 |
ASPRUZYO SPRINKLE ER 500 MG PKT | RANOLAZINE | 07/03/2022 | 08/16/2022 | Clinical Edit | December 2022 / January 2022 |
AMVUTTRA 25 MG/0.5 ML SYRINGE | VUTRISIRAN SODIUM | 06/26/2022 | 08/16/2022 | PDL Product | September 2022 / October 2022 |
SKYRIZI 600 MG/10 ML VIAL | RISANKIZUMAB-RZAA | 06/26/2022 | 08/11/2022 | PDL Product | September 2022 / October 2022 |
SKYRIZI 360 MG/2.4 ML ON-BODY | RISANKIZUMAB-RZAA | 06/26/2022 | 08/11/2022 | Clinical Edit | September 2022 / October 2022 |
OLUMIANT 4 MG TABLET | BARICITINIB | 06/19/2022 | 08/02/2022 | PDL Edit | September 2022 / October 2022 |